Literature DB >> 1904452

Depot leuprolide acetate dosage for sexual precocity.

K L Parker1, R G Baens-Bailon, P A Lee.   

Abstract

Twenty-one children with early puberty have been evaluated to determine adequate dosage of depot leuprolide acetate. The minimal dosage of depot leuprolide acetate required, using intervals of 1.5 mg or less when given every 28 days, was determined. This dosage, as determined by suppression of gonadotropin responses to GnRH stimulation, was 4.14 +/- 1.33 mg (mean +/- SD) and 0.15 +/- 0.07 mg/kg.28 days. The dosage correlates with bone age and pubertal stage and is larger among patients with more advanced puberty. Five patients required a larger dosage from 5-10 months after initial suppression. Therefore, to monitor suppression, GnRH testing should be repeated at least at 6-month intervals. Samples 20 and 40 min after GnRH stimulation are sufficient to indicate adequacy of treatment, so an abbreviated test could be used.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1904452     DOI: 10.1210/jcem-73-1-50

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

1.  Urinary metabolite markers of precocious puberty.

Authors:  Ying Qi; Pin Li; Yongyu Zhang; Lulu Cui; Zi Guo; Guoxiang Xie; Mingming Su; Xin Li; Xiaojiao Zheng; Yunping Qiu; Yumin Liu; Aihua Zhao; Weiping Jia; Wei Jia
Journal:  Mol Cell Proteomics       Date:  2011-10-25       Impact factor: 5.911

2.  Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty.

Authors:  Shrikrishna V Acharya; Raju A Gopal; Joe George; Tushar R Bandgar; Padma S Menon; Nalini S Shah
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

3.  Gonadal steroid modulation of the limbic-hypothalamic- pituitary-adrenal (LHPA) axis is influenced by social status in female rhesus monkeys.

Authors:  Mark E Wilson; Ariadne Legendre; Karen Pazol; Jeffrey Fisher; Kathy Chikazawa
Journal:  Endocrine       Date:  2005-03       Impact factor: 3.633

4.  Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot.

Authors:  V N de Brito; A C Latronico; I J Arnhold; L S Lo; S Domenice; M C Albano; M C Fragoso; B B Mendonca
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

Review 5.  Central precocious puberty: current treatment options.

Authors:  Franco Antoniazzi; Giorgio Zamboni
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

6.  Precocious puberty: auxological criteria discriminating different forms.

Authors:  F Bassi; O Bartolini; A S Neri; R G Gheri; S Bucciantini; D Cheli; V Bruni
Journal:  J Endocrinol Invest       Date:  1994-11       Impact factor: 4.256

Review 7.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders.

Authors:  G L Plosker; R N Brogden
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

Review 8.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

9.  GnRH stimulation test in precocious puberty: single sample is adequate for diagnosis and dose adjustment.

Authors:  Nurgün Kandemir; Hüseyin Demirbilek; Zeynep Alev Özön; Nazlı Gönç; Ayfer Alikaşifoğlu
Journal:  J Clin Res Pediatr Endocrinol       Date:  2011-02-23

10.  Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.

Authors:  Samar Rahhal; William L Clarke; Gad B Kletter; Peter A Lee; E Kirk Neely; Edward O Reiter; Paul Saenger; Dorothy Shulman; Lawrence Silverman; Erica A Eugster
Journal:  Int J Pediatr Endocrinol       Date:  2009-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.